115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
乌帕替尼治疗获得性反应性穿刺性胶原病：1 例病例报告及文献复习
Authors Xie B , Zhang X, Lei X, Zhang Y, Zhang Q, Ye Y
Received 2 October 2025
Accepted for publication 25 December 2025
Published 7 January 2026 Volume 2026:19 569903
DOI https://doi.org/10.2147/CCID.S569903
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Rungsima Wanitphakdeedecha
Bo Xie,* Xiaoyan Zhang,* Xinxin Lei,* Yuting Zhang, Qin Zhang, Yujian Ye
Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310009, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yujian Ye, Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Westlake Road 38, Hangzhou, 310009, People’s Republic of China, Email yeyujian@hotmail.com
Abstract: Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis linked to systemic diseases, with unclear pathogenesis and no standardized therapy. We report a 53-year-old male with ARPC who failed conventional treatments but improved rapidly with upadacitinib 15 mg/day for one month, followed by 15 mg every other day. After three months, most lesions resolved, leaving hyperpigmentation and scars. Literature review shows conflicting reports: one case of ARPC improved with upadacitinib, another developed ARPC during upadacitinib treatment for atopic dermatitis. Our findings suggest upadacitinib may be effective for ARPC, especially in pruritic patients, regardless of diabetes status.
Keywords: Janus kinase inhibitor, reactive perforating collagenosis, upadacitinib
Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310009, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yujian Ye, Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Westlake Road 38, Hangzhou, 310009, People’s Republic of China, Email yeyujian@hotmail.com
Abstract: Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis linked to systemic diseases, with unclear pathogenesis and no standardized therapy. We report a 53-year-old male with ARPC who failed conventional treatments but improved rapidly with upadacitinib 15 mg/day for one month, followed by 15 mg every other day. After three months, most lesions resolved, leaving hyperpigmentation and scars. Literature review shows conflicting reports: one case of ARPC improved with upadacitinib, another developed ARPC during upadacitinib treatment for atopic dermatitis. Our findings suggest upadacitinib may be effective for ARPC, especially in pruritic patients, regardless of diabetes status.
Keywords: Janus kinase inhibitor, reactive perforating collagenosis, upadacitinib